Author: Richard Atkins

Richard Atkins is a senior contributor at Tech Insider covering online media, online travel, and video games. Richard has been with Tech Insider covering companies in these industries since 2011 and has authored numerous industry reports, including "Internet Video: Field of Dreams or Nightmare on Elm Street," "The Next Leg of Online Travel," and "Pwned: How Casual Games Changed The Gaming Landscape." Atkins was recognized as the No. 2 stock picker and earnings estimator in the 2011 Financial Times / StarMine Internet & Catalog Retail category and was ranked in the 2010 Wall Street Journal "Best On The Street" for the Leisure Goods & Services category.
Biotech Finance News
BioTech, Finance

Biotech Stock Incyte Receives $60M Milestone Payment

Last week, Incyte Corporation (INCY) received a milestone payment of $60 million from Novartis (NVS) pertaining to the reimbursement of Jakavi in Europe. The drug has been approved by the European Commission to treat adults suffering from primary myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. It is a common practice of small pharma companies to enter into agreements with larger pharma companies for … Continue reading Biotech Stock Incyte Receives $60M Milestone Payment

Richard Atkins
Analysis, Finance, Software

Bitcoin News: Romania Crosses Over 800 Bitcoin Payment Terminals

Bitcoin is now available at 874 self-service payment terminals across Romania, thanks to a partnership between ATM operator Bitcoin Romania and terminal network operator ZebraPay. The ZebraPay terminals will allow customers to buy bitcoin at a 4% commission on prices taken from the Cointrader exchange. The terminals are one-way, so customers can only trade their Romanian leu for bitcoin. The terminals do not require customers … Continue reading Bitcoin News: Romania Crosses Over 800 Bitcoin Payment Terminals

Richard Atkins
Finance, Mobile

Stock in Focus: Apple (NASDAQ APPL) Gears Up For Next Week’s Event

On Wednesday, Apple Inc (NASDAQ AAPL) sent invitations to media for an Oct. 16 event using the teaser “It’s been way too long.” Media and market watchers are guessing that in the event, the company will launch refreshed versions of its iPads and Macs. Apple Inc.’s big event is expected to bring revamped and new models of iPads and MacBooks. Last year in October, the … Continue reading Stock in Focus: Apple (NASDAQ APPL) Gears Up For Next Week’s Event

Richard Atkins
Finance, Internet

Active Stock: What is Facebook (NASDAQ FB) Planning For WhatsApp

Facebook Inc (NASDAQ FB) has spent a large amount in acquiring WhatsApp, the most popular messaging app, and this acquisition has come at a huge cost of more than $19 billion. Though the general perception might be that Facebook would want to monetize its investments and seek good returns ASAP, a report indicates that the social network has no such plans for the time being. … Continue reading Active Stock: What is Facebook (NASDAQ FB) Planning For WhatsApp

Richard Atkins
Finance, Internet

Microsoft Looking For No Email Attachments

Microsoft Corporation (NASDAQ MSFT) wants to make things a little bit easier for it’s email users. The company’s Outlook Web App simplifies everything by allowing users to send links to attachments stored on OneDrive for Business.Microsoft thinks the process of attaching, opening, modifying, and re-sending documents takes too much time. The new Outlook Web and OneDrive for Business apps will make sharing and collaborating that … Continue reading Microsoft Looking For No Email Attachments

Richard Atkins
Biotech Stock Finance Bio Tech
BioTech, Finance

Biotech Stock News: Regeneron’s Eylea Gets An Important Approval From FDA

Good news flowed in at Regeneron Pharmaceuticals (REGN) when the FDA cleared the company’s highly successful injectable eye drug for macular edema following retinal vein occlusion (RVO), a common retinal vascular disorder. Approval for the broad RVO indication includes sub-indications like, macular edema following branch retinal vein occlusion (BRVO) and macular edema following central retinal vein occlusion (CRVO). We remind investors that Eylea is already … Continue reading Biotech Stock News: Regeneron’s Eylea Gets An Important Approval From FDA

Richard Atkins